Skip to content

Q-fever post-vaccination study

Q-fever post-vaccination study - Q-fever post-vaccination study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON35763
Enrollment
400
Registered
2011-05-24
Start date
2011-08-31
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coxiella burnetii infection Q-fever

Interventions

None listed

Sponsors

RIVM
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Signed Informed Consent - willing to adhere to blood draw schedule - has taken part in the national Q-fever vaccination campaign

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

MeasureTime frame
Humoral immune response: IgG and IgM antibodies against fase 1 and 2 antigens of C. burnetii are measured by means of several serological tests:: immune fluorescence assay (IFA), enzyme-linked immuno sorbent assay (ELISA), complement binding reaction (CBR), polymerase chain reaction (PCR) and micro-array. Cellular immune response: After stimulation of whole blood, the levels of interferon-gamma (IFN-gamma), interleukine (IL)-10 and possibly IL-12 production are measured. Also a T-helper 1 and T-helper 2 cytokine profile are measured in isolated mononuclear cells, isolated CD14+ monocytes and isolated T-cells after stimulation, and differentiation of the cells is studied.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)